Abbott's libre® technology is first continuous glucose monitor associated with reduced hospitalizations for heart complications in people with diabetes

New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with type 1 diabetes with prior severe low blood sugar episodes.1 this significant decrease is linked to the use of libre biowearable technology compared to traditional blood glucose monitors.1 results also show a reduction in hospitalization for cardiovascular complications in adults with type 2 diabetes on insulin using libre technology.2 abbott park, ill., may 15, 2025 /prnewswire/ -- abbott (nyse: abt) today announced results from its reflect real-world studies that show the use of freestyle libre® continuous glucose monitoring (cgm) technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes.
ABT Ratings Summary
ABT Quant Ranking